At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 10 enrolled
Drug / intervention
Viekira Pak ± ribavirin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Efficacy, and Changes in Traditional and Novel Biomarkers of Kidney Function in Patients With Hepatitis C and Advanced Chronic Kidney Disease Treated With Abbvie Viekira Pak or Mavyret Regimen
In Brief
A Phase 4 clinical trial evaluating Viekira Pak ± ribavirin and Mavyret for Chronic Kidney Disease and Chronic Hepatitis C. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease, Chronic Hepatitis C
CountriesUnited States
CollaboratorsAbbVie
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartFeb 2017
Primary CompletionSep 2020
TodayJul 2026
First PostedOct 26, 2016
Enrollment StartFeb 1, 2017
Primary CompletionSep 16, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.7 years ago
Interventions
Viekira Pak ± ribavirindrug
12 weeks treatment with AbbVie Viekira Pak ± ribavirin
Mavyretdrug
8 or 12 weeks treatment with AbbVie Mavyret